Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Yes you may ask ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Feb 08, 2021 8:22pm
118 Views
Post# 32508503

RE:RE:Yes you may ask ...

RE:RE:Yes you may ask ...
longrun86 wrote: Amen to that!

Constructive information and opinions are what I am looking for in this message board.

I am looking for absolute returns over a long time horizon. As long as I believe in a Management team's ability and strategy I will stick with an investment. If I disagree with Management, the best bet is for me to move on as I am unlikely to change their minds.

I have learned more about the economic profile of South America in the past three weeks than in my entire life and I look forward to continuing that learning with my holding in Knight.


Well said Longrun!
Lots for us to learn about S.America and how GUD plans to hedge bets there in the future.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities